Patents by Inventor Zoar Jacob ENGELMAN
Zoar Jacob ENGELMAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11844569Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: August 15, 2023Date of Patent: December 19, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
-
Publication number: 20230380901Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: August 15, 2023Publication date: November 30, 2023Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
-
Publication number: 20230380896Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: August 7, 2023Publication date: November 30, 2023Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
-
Patent number: 11806073Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: October 22, 2021Date of Patent: November 7, 2023Assignee: Axon Therapies, Inc.Inventors: Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Jr.
-
Patent number: 11801092Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.Type: GrantFiled: October 26, 2021Date of Patent: October 31, 2023Assignee: Axon Therapies, Inc.Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
-
Patent number: 11751939Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: January 28, 2019Date of Patent: September 12, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
-
Patent number: 11712296Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: February 18, 2020Date of Patent: August 1, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung, Howard Levin
-
Publication number: 20230165634Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: November 21, 2022Publication date: June 1, 2023Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
-
Patent number: 11504185Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: June 11, 2021Date of Patent: November 22, 2022Assignee: Axon Therapies, Inc.Inventors: Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Nicholas C. VanDillen, Anne Marie Ahonen
-
Publication number: 20220257315Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.Type: ApplicationFiled: October 26, 2021Publication date: August 18, 2022Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
-
Patent number: 11413090Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: January 19, 2021Date of Patent: August 16, 2022Assignee: Axon Therapies, Inc.Inventors: Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Jr., Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Nicholas C. VanDillen, Anne Marie Ahonen
-
Publication number: 20220039863Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: October 22, 2021Publication date: February 10, 2022Inventors: Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan MCGRATH, Manuel Arzadon JAVIER, JR.
-
Patent number: 11154354Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.Type: GrantFiled: July 31, 2017Date of Patent: October 26, 2021Assignee: Axon Therapies, Inc.Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
-
Publication number: 20210298824Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: June 11, 2021Publication date: September 30, 2021Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
-
Publication number: 20210220043Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: January 19, 2021Publication date: July 22, 2021Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, JR., Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
-
Publication number: 20210128229Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: January 28, 2019Publication date: May 6, 2021Applicant: AXON THERAPIES, INC.Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
-
Publication number: 20200179047Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: February 18, 2020Publication date: June 11, 2020Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG, Howard LEVIN
-
Publication number: 20200179045Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.Type: ApplicationFiled: July 31, 2017Publication date: June 11, 2020Applicant: AXON THERAPIES, INC.Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
-
Publication number: 20200093505Abstract: Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation. The methods may be performed using an ultrasound ablation catheter. The methods may also include imaging using at least one ultrasound imaging catheter.Type: ApplicationFiled: November 13, 2019Publication date: March 26, 2020Inventors: Yegor D. SINELNIKOV, Zoar Jacob ENGELMAN, Mark GELFAND, Martin M. GRASSE, Timothy A. KOSS, Michael Brick MARKHAM, Kenneth M. MARTIN, Veijo T. SUORSA, Miriam H. TAIMISTO, Xian WEI, Brice Arnault DE LA MENARDIERE, Clayton Miles BALDWIN, Jason Michael MILLER
-
Patent number: 10561461Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: December 17, 2018Date of Patent: February 18, 2020Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung, Howard Levin